World journal of clinical cases · 2025
Ulcerative colitis and bullous pemphigoid: Direct association or a medication side effect: A case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Haddad Gaelle-Christie, El Dada Anthony, Sbeih Sergio, Kazzi Tony, Karam Karam, Chaptini Louis A
Аннотация
BACKGROUND: Bullous pemphigoid (BP) is an autoimmune blistering skin disorder. It is associated with other autoimmune disorders and the use of certain drugs. We describe a case of BP in a patient with ulcerative colitis (UC) treated with mesalamine.
CASE SUMMARY: A 38-year-old male patient with UC and a history of multiple flares was maintained on mesalamine with good clinical response. One year after starting mesalamine, he sought medical care following the onset of a severe itchy rash of several weeks' duration with a recent appearance of skin bullae. A biopsy of the skin revealed subepidermal blistering dermatitis with focal eosinophilic spongiosis. Direct immunofluorescence studies revealed linear IgG and C3 immune reactant deposits at the dermoepidermal junction, consistent with the diagnosis of BP. Prednisone therapy alleviated his symptoms. However, tapering prednisone led to re-eruption of the bullae.
CONCLUSION: BP should be considered when patients with UC develop skin manifestations. Although BP is not one of the extraintestinal manifestations of UC, there may be an association between these two conditions. Whether treatment with mesalamine or other therapeutic agents plays a role in the development of BP remains unclear.
CASE SUMMARY: A 38-year-old male patient with UC and a history of multiple flares was maintained on mesalamine with good clinical response. One year after starting mesalamine, he sought medical care following the onset of a severe itchy rash of several weeks' duration with a recent appearance of skin bullae. A biopsy of the skin revealed subepidermal blistering dermatitis with focal eosinophilic spongiosis. Direct immunofluorescence studies revealed linear IgG and C3 immune reactant deposits at the dermoepidermal junction, consistent with the diagnosis of BP. Prednisone therapy alleviated his symptoms. However, tapering prednisone led to re-eruption of the bullae.
CONCLUSION: BP should be considered when patients with UC develop skin manifestations. Although BP is not one of the extraintestinal manifestations of UC, there may be an association between these two conditions. Whether treatment with mesalamine or other therapeutic agents plays a role in the development of BP remains unclear.